Precision BioSciences Inc
DTIL
查看详细走势图
5.510USD
-1.030-15.75%
交易中 （美东）报价延迟15分钟
9.00M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-15.75%
5天
-15.49%
1月
+31.19%
6月
+8.25%
今年开始到现在
+32.45%
1年
+17.23%
查看详细走势图
TradingKey Precision BioSciences Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
Precision BioSciences Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名105/391位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价32.00。中期看，股价处于上升通道。近一个月，市场表现很强，技术面评分较高，但很强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Precision BioSciences Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Precision BioSciences Inc亮点
亮点风险
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
业绩增长期
公司处于发展阶段，最新年度总收入34.26M美元
业绩转亏
公司业绩转亏，最新年度亏损美元
估值低估
公司最新PE估值-1.69，处于3年历史低位
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值326.48K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.91
分析师目标
根据
4
位分析师
强力买入
评级
32.000
目标均价
+389.30%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Precision BioSciences Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Precision BioSciences Inc简介
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
公司代码DTIL
公司Precision BioSciences Inc
CEOAmoroso (Michael)
网址https://precisionbiosciences.com/
相关品种
